XML 28 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
 
Balance at Beginning of Period
 
Charged to Costs and Expenses
 
Other
 
Deductions
 
Balance at End of Period
Description
 
 
 
 
 
(In thousands)
 
 
Year ended December 31, 2019
 
 
 
 
 
 
 
 
 
Allowance for doubtful accounts
3,719

 
2,126

 
—

 
(1,542
)
(2) 
4,303

Deferred tax assets valuation allowance
6,973

 
3,848

 
1,291

(4) 
(43
)
 
12,069

Year ended December 31, 2018
 
 
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
8,882

 
$
557

 
$
(4,649
)
(3) 
$
(1,071
)
(2) 
$
3,719

Deferred tax assets valuation allowance
7,961

 
(894
)
 
—

 
(94
)
 
6,973

Year ended December 31, 2017
 
 
 
 
 
 
 
 
 
Allowance for doubtful accounts and sales returns and allowances
$
6,319

 
$
4,920

 
$
1,518

(1) 
(3,875
)
(2) 
$
8,882

Deferred tax assets valuation allowance
3,604

 
740

 
3,617

(1) 
—

 
7,961

(1) 
The above amounts primarily relate to amounts acquired through acquisition of Derma Sciences and effect of foreign currency translations.
(2) 
Deductions primarily relates to allowance for doubtful accounts written off during the year, net of recoveries and other adjustments.
(3) 
The Company transferred sales returns and allowances from accounts receivable, net to accrued expenses and other current liabilities upon adopting Topic 606 on January 1, 2018 using the modified retrospective method.
(4) 
The above amount primarily relates to amounts acquired through the acquisition of Arkis and a charge recorded in 2019 to valuation allowance related to the non-deductibility of executive compensation.